Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
VSV-Based Recombinant Oncolytic Viruses in Advanced Malignant Tumors
NCT07656116Phase 1Recruiting
- Sponsor
- Cancer Institute and Hospital, Chinese Academy of Medical Sciences
- Start
- Jan 2026
- Primary completion
- Jan 2027
- Countries
- 1
01
Overview
Phase 1, open-label trial of vesicular stomatitis virus in solid tumor (advanced stage) (3 arms), sponsored by Cancer Institute and Hospital, Chinese Academy of Medical Sciences. Primary endpoints: Incidence of Dose-Limiting Toxicities at 21 days and Incidence of Adverse Events at 24 months. Started Jan 2026; status: recruiting.
02
Drugs
vesicular stomatitis virus
03
Conditions
solid tumor (advanced stage)
Beyond the preview
Go deeper on NCT07656116.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07656116.